Cell Line Development Market Future Growth Analysis And Forecast To 2022| Grand View Research, Inc
“The global cell line development market size was estimated at USD 2.67 billion in 2015 and is anticipated to grow at a CAGR of 12.9% over the forecast period .�
Global cell line development market size is expected to reach USD 6.24 billion by 2022, according to a new report by Grand View Research, Inc. The Increasing demand for monoclonal antibodies and patent expiration of blockbuster biologics are expected to drive the cell line development industry over the forecast period. Increasing prevalence of autoimmune diseases and cancer are likely to increase the demand for accurate and cost effective treatment options which is expected to render a positive impact on market growth. In addition, improving healthcare infrastructure, economic development and favorable government initiatives promoting the growth of the biotechnology industry are factors contributing towards the growth of the cell line development market. Ongoing R&D for stable & authentic cell lines and the introduction of technologically advanced processes such as single use bioreactor and micro bioreactor for large scale bioproduction are further expected to provide this market with lucrative future growth opportunities.
Browse Details of Report @ www.grandviewresearch.com/industry-analysis/cell-line-development-market
Follow Us:
Further key findings from the study suggest:
Reagent and media was the largest product market in 2014, owing to increasing number of cell culture procedures. Reagent and media are necessary components involved in cell line development procedures & cell culture and are cost intensive in nature. The market for reagent and media was valued at over 1.0 billion in 2014.
Mammalian cell lines were widely used as a source for cell line development in 2014, owing to associated advantages such as accurate complex protein expression nature, critical for the production of monoclonal antibodies, vaccines, and biologics.
Cell line development finds the largest application in the bioproduction of biologics, vaccines, Mabs, therapeutic proteins and biosimilars. Rising demand for monoclonal antibodies and vaccines are expected to boost the growth of this segment over the forecast period. The market for cell line development based bioproduction is also expected to witness lucrative growth of over 12.5% during the forecast period.
North America was the largest market in 2014, with revenue estimated at over 800 million. The region’s market dominance is attributed to factors such as the growing adoption rates of cell culture techniques, presence of well developed healthcare infrastructure, supportive government initiatives and high healthcare expenditure levels.
Asia Pacific cell line development market is anticipated to register rapid growth over the forecast period owing to factors such as the presence of high unmet needs, rising number of CROs (Contract Research Organization) providing pertinent services, growing R&D investments aimed at the development of stable cell lines and increasing biologics production.
Key players in this market include European Collection of cell Cultures (ECACC), Lonza Group AG, GE Healthcare, Thermo Fisher Scientific Inc., Sartorious AG, Selexis SA, Wuxi AppTec Inc., Sigma-Aldrich Corporation, American Type Culture Collection (ATCC) and Corning Inc.
Grand View Research has segmented the global cell line development market on the basis of product, source, type of cell line, application and region: Global Cell Line Development Product Outlook (Revenue, USD Million, 2012 - 2022) o Reagents and media o
Equipment Accessories and consumables
Incubators
Centrifuges
Bioreactors
Storage equipment
Microscopes
Global Cell Line Development Source Outlook (Revenue, USD Million, 2012 - 2022) o Mammalian o
Follow Us:
Non mammalian
Insects
Amphibians
Global Cell Line Development Type Of Cell Line Outlook (Revenue, USD Million, 2012 - 2022) o Recombinant cell lines o
Hybridomas
o
Continuous cell line
o
Primary cell lines
Global Cell Line Development Application Outlook (Revenue, USD Million, 2012 - 2022) o Bioproduction o
Drug discovery
o
Toxicity testing
o
Tissue engineering
o
Research
Cell Line Development Regional Outlook (Revenue, USD Billion, 2014 - 2022) o North America
o
o
o
o
U.S.
Canada
Europe
Germany
UK
Asia Pacific
China
Japan
India
Latin America
Mexico
Brazil
MEA
South Africa
Browse Related Category Reports @ www.grandviewresearch.com/industry/biotechnology
Follow Us:
Table of Content of Cell Line Development Market Chapter 1. Methodology and Scope 1.1. Research methodology 1.2. Research scope &assumption 1.3. List of data sources Chapter 2. Executive Summary 2.1. Cell Line Development - Industry Snapshot and Key Buying Criteria, 2012 - 2022 Chapter 3. Cell Line Development Industry Outlook 3.1. Cell line development market segmentation 3.2. Cell line development market size and growth prospects, 2012 - 2022 3.3. Cell line development market dynamics 3.3.1. Market driver analysis 3.3.2. Market restraint analysis 3.4. Key opportunities prioritized 3.5. Industry Analysis - Porter's 3.6. Cell line development competitive landscape, 2014 3.6.1. Company market share analysis, 2014 3.6.2. Market position analysis, 2014 (based on products, regional presence, and strategic initiatives) 3.7. Cell line development market PESTEL analysis, 2014 Chapter 4. Cell Line Development Product Outlook 4.1. Cell line development market share by product, 2014 & 2022 4.2. Reagents and media 4.2.1. Reagents and media market estimates and forecasts, 2012 - 2022 (USD million) 4.3. Equipment 4.3.1. Equipment market estimates and forecasts, 2012 - 2022 (USD million) 4.3.2. Incubators 4.3.2.1. Incubators market estimates and forecasts, 2012 - 2022 (USD million) 4.3.3. Centrifuges 4.3.3.1. Centrifuges market estimates and forecasts, 2012 - 2022 (USD million) 4.3.4. Bioreactors 4.3.4.1. Bioreactors market estimates and forecasts, 2012 - 2022 (USD million)
Follow Us:
4.3.5. Storage equipment 4.3.5.1. Storage equipment market estimates and forecasts, 2012 - 2022 (USD million) 4.3.6. Microscopes 4.3.6.1. Microscopes market estimates and forecasts, 2012 - 2022 (USD million) 4.4. Accessories and consumables 4.4.1. Accessories and consumables market estimates and forecasts, 2012 - 2022 (USD million) Chapter 5. Cell Line Development Source Outlook 5.1. Cell line development market share by source, 2014 & 2022 5.2. Mammalian 5.2.1. Mammalian market estimates and forecasts, 2012 - 2022 (USD million) 5.3. Non-mammalian 5.3.1. Non-mammalian market estimates and forecasts, 2012 - 2022 (USD million) 5.3.2. Insects 5.3.2.1. Insects market estimates and forecasts, 2012 - 2022 (USD million) 5.3.3. Amphibians 5.3.3.1. Amphibians market estimates and forecasts, 2012 - 2022 (USD million) Chapter 6. Cell Line Development Type of Cell Lines Outlook 6.1. Cell line development market share, by type of cell lines, 2014 & 2022 6.2. Recombinant cell lines 6.2.1. Recombinant cell lines market estimates and forecasts, 2012 - 2022 (USD million) 6.3. Hybridomas 6.3.1. Hybridomas market estimates and forecasts, 2012 - 2022 (USD million) 6.4. Continuous cell lines 6.4.1. Continuous cell lines market estimates and forecasts, 2012 - 2022 (USD million) 6.5. Primary cell lines 6.5.1. Primary cell lines market estimates and forecasts, 2012 - 2022 (USD million) Chapter 7. Cell Line Development Application Outlook 7.1. Cell line development market share, by application, 2014 & 2022 7.2. Bioproduction 7.2.1. Bioproduction market estimates and forecasts, 2012 - 2022 (USD million) 7.3. Drug discovery 7.3.1. Drug discovery market estimates and forecasts, 2012 - 2022 (USD million)
Follow Us:
7.4. Toxicity testing 7.4.1. Toxicity testing market estimates and forecasts, 2012 - 2022 (USD million) 7.5. Vaccines 7.5.1. Vaccines market estimates and forecasts, 2012 - 2022 (USD million) 7.6. Tissue engineering 7.6.1. Tissue engineering market estimates and forecasts, 2012 - 2022 (USD million) 7.7. Others 7.7.1. Others market estimates and forecasts, 2012 - 2022 (USD million) Chapter 8. Cell Line Development Regional Outlook 8.1. Cell line development market share, by region, 2014 & 2022 8.2. North America 8.2.1. North America cell line development market estimates and forecasts, by product, 2012 - 2022 (USD million) 8.2.1.1. U.S. 8.2.1.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.2.1.2. Canada 8.2.1.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.2.2. North America cell line development market estimates and forecasts, by source, 2012 - 2022 (USD million) 8.2.2.1. U.S. 8.2.2.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.2.2.2. Canada 8.2.2.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.2.3. North America cell line development market estimates and forecasts, by type of cell lines, 2012 2022 (USD million) 8.2.3.1. U.S. 8.2.3.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.2.3.2. Canada 8.2.3.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.2.4. North America cell line development market estimates and forecasts, by application, 2012 - 2022 (USD million) 8.2.4.1. U.S.
Follow Us:
8.2.4.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.2.4.2. Canada 8.2.4.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.3. Europe 8.3.1. Europe cell line development market estimates and forecasts, by product, 2012 - 2022 (USD million) 8.3.1.1. UK 8.3.1.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.3.1.2. Germany 8.3.1.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.3.2. Europe cell line development market estimates and forecasts, by source, 2012 - 2022 (USD million) 8.3.2.1. UK 8.3.2.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.3.2.2. Germany 8.3.2.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.3.3. Europe cell line development market estimates and forecasts, by type of cell lines, 2012 - 2022 (USD million) 8.3.3.1. UK 8.3.3.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.3.3.2. Germany 8.3.3.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.3.4. Europe cell line development market estimates and forecasts, by application, 2012 - 2022 (USD million) 8.3.4.1. UK 8.3.4.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.3.4.2. Germany 8.3.4.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.4. Asia Pacific 8.4.1. Asia Pacific cell line development market estimates and forecasts, by product, 2012 - 2022 (USD million) 8.4.1.1. Japan 8.4.1.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.4.1.2. China
Follow Us:
8.4.1.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.4.1.3. India 8.4.1.3.1. Cell line development market estimates and forecasts, 2012 - 2022 8.4.2. Asia Pacific cell line development market estimates and forecasts, by source, 2012 - 2022 (USD million) 8.4.2.1. Japan 8.4.2.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.4.2.2. China 8.4.2.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.4.2.3. India 8.4.2.3.1. Cell line development market estimates and forecasts, 2012 - 2022 8.4.3. Asia Pacific cell line development market estimates and forecasts, by type of cell lines, 2012 - 2022 (USD million) 8.4.3.1. Japan 8.4.3.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.4.3.2. China 8.4.3.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.4.3.3. India 8.4.3.3.1. Cell line development market estimates and forecasts, 2012 - 2022 8.4.4. Asia Pacific cell line development market estimates and forecasts, by application, 2012 - 2022 (USD million) 8.4.4.1. Japan 8.4.4.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.4.4.2. China 8.4.4.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.4.4.3. India 8.4.4.3.1. Cell line development market estimates and forecasts, 2012 - 2022 8.5. Latin America 8.5.1. Latin America cell line development market estimates and forecasts, by product, 2012 - 2022 (USD million) 8.5.1.1. Mexico 8.5.1.1.1. Cell line development market estimates and forecasts, 2012 - 2022
Follow Us:
8.5.1.2. Brazil 8.5.1.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.5.2. Latin America cell line development market estimates and forecasts, by source, 2012 - 2022 (USD million) 8.5.2.1. Mexico 8.5.2.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.5.2.2. Brazil 8.5.2.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.5.3. Latin America cell line development market estimates and forecasts, by type of cell lines, 2012 - 2022 (USD million) 8.5.3.1. Mexico 8.5.3.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.5.3.2. Brazil 8.5.3.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.5.4. Latin America cell line development market estimates and forecasts, by application, 2012 - 2022 (USD million) 8.5.4.1. Mexico 8.5.4.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.5.4.2. Brazil 8.5.4.2.1. Cell line development market estimates and forecasts, 2012 - 2022 8.6. MEA 8.6.1. MEA cell line development market estimates and forecasts, by product, 2012 - 2022 (USD million) 8.6.1.1. South Africa 8.6.1.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.6.2. MEA cell line development market estimates and forecasts, by source, 2012 - 2022 (USD million) 8.6.2.1. South Africa 8.6.2.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.6.3. MEA cell line development market estimates and forecasts, by type of cell lines, 2012 - 2022 (USD million) 8.6.3.1. South Africa 8.6.3.1.1. Cell line development market estimates and forecasts, 2012 - 2022 8.6.4. MEA cell line development market estimates and forecasts, by application, 2012 - 2022 (USD million)
Follow Us:
8.6.4.1. South Africa 8.6.4.1.1. Cell line development market estimates and forecasts, 2012 - 2022 Chapter 9. Competitive Landscape 9.1. General Electric Company (GE Healthcare) 9.1.1. Company Overview 9.1.2. Financial Performance 9.1.3. Product Benchmarking 9.1.4. Strategic Initiatives 9.2. Thermo Fisher Scientific Inc. 9.2.1. Company Overview 9.2.2. Financial Performance 9.2.3. Product Benchmarking 9.2.4. Strategic Initiatives 9.3. Public Health England (European Collection of Cell Cultures) 9.3.1. Company Overview 9.3.2. Financial Performance 9.3.3. Product Benchmarking 9.3.4. Strategic Initiatives 9.4. Lonza 9.4.1. Company Overview 9.4.2. Financial Performance 9.4.3. Product Benchmarking 9.4.4. Strategic Initiatives 9.5. Sigma-Aldrich Co. 9.5.1. Company Overview 9.5.2. Financial Performance 9.5.3. Product Benchmarking 9.5.4. Strategic Initiatives 9.6. WuXi AppTec 9.6.1. Company Overview 9.6.2. Financial Performance 9.6.3. Product Benchmarking
Follow Us:
9.6.4. Strategic Initiatives 9.7. ATCC (American Type Culture Collection) 9.7.1. Company Overview 9.7.2. Financial Performance 9.7.3. Product Benchmarking 9.7.4. Strategic Initiatives 9.8. Sartorius AG 9.8.1. Company Overview 9.8.2. Financial Performance 9.8.3. Product Benchmarking 9.8.4. Strategic Initiatives 9.9. Corning Incorporated 9.9.1. Company Overview 9.9.2. Financial Performance 9.9.3. Product Benchmarking 9.9.4. Strategic Initiatives 9.10. Selexis 9.10.1. Company Overview 9.10.2. Financial Performance 9.10.3. Product Benchmarking 9.10.4. Strategic Initiatives 9.11. Vista Biologicals Corporation 9.11.1. Company Overview 9.11.2. Financial Performance 9.11.3. Product Benchmarking 9.11.4. Strategic Initiatives 9.12. Eubiologics CO., LTD. 9.12.1. Company Overview 9.12.2. Financial Performance 9.12.3. Product Benchmarking 9.12.4. Strategic Initiatives 9.13. Paragon Bioservices, Inc.
Follow Us:
9.13.1. Company Overview 9.13.2. Financial Performance 9.13.3. Product Benchmarking 9.13.4. Strategic Initiatives 9.14. Cobra Biologics 9.14.1. Company Overview 9.14.2. Financial Performance 9.14.3. Product Benchmarking 9.14.4. Strategic Initiatives 9.15. Gallus Biopharmaceuticals (Acquired by Patheon) 9.15.1. Company Overview 9.15.2. Financial Performance 9.15.3. Product Benchmarking 9.15.4. Strategic Initiatives 9.16. Samsung Biologics 9.16.1. Company Overview 9.16.2. Financial Performance 9.16.3. Product Benchmarking 9.16.4. Strategic Initiatives 9.17. Naeja 9.17.1. Company Overview 9.17.2. Financial Performance 9.17.3. Product Benchmarking 9.17.4. Strategic Initiatives 9.18. Aragen Bioscience 9.18.1. Company Overview 9.18.2. Financial Performance 9.18.3. Product Benchmarking 9.18.4. Strategic Initiatives 9.19. GVK BIO 9.19.1. Company Overview 9.19.2. Financial Performance
Follow Us:
9.19.3. Product Benchmarking 9.19.4. Strategic Initiatives 9.20. PCT 9.20.1. Company Overview 9.20.2. Financial Performance 9.20.3. Product Benchmarking 9.20.4. Strategic Initiatives 9.21. Apath 9.21.1. Company Overview 9.21.2. Financial Performance 9.21.3. Product Benchmarking 9.21.4. Strategic Initiatives 9.22. Cell for cure 9.22.1. Company Overview 9.22.2. Financial Performance 9.22.3. Product Benchmarking 9.22.4. Strategic Initiatives 9.23. TRL 9.23.1. Company Overview 9.23.2. Financial Performance 9.23.3. Product Benchmarking 9.23.4. Strategic Initiatives 9.24. Episteme 9.24.1. Company Overview 9.24.2. Financial Performance 9.24.3. Product Benchmarking 9.24.4. Strategic Initiatives 9.25. Catalent 9.25.1. Company Overview 9.25.2. Financial Performance 9.25.3. Product Benchmarking 9.25.4. Strategic Initiatives
Follow Us:
9.26. Bioceros 9.26.1. Company Overview 9.26.2. Financial Performance 9.26.3. Product Benchmarking 9.26.4. Strategic Initiatives 9.27. Antitope 9.27.1. Company Overview 9.27.2. Financial Performance 9.27.3. Product Benchmarking 9.27.4. Strategic Initiatives 9.28. Promocell 9.28.1. Company Overview 9.28.2. Financial Performance 9.28.3. Product Benchmarking 9.28.4. Strategic Initiatives 9.29. Cyagen 9.29.1. Company Overview 9.29.2. Financial Performance 9.29.3. Product Benchmarking 9.29.4. Strategic Initiatives
Follow Us:
About Us: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Email: sales@grandviewresearch.com For More Information: http://www.grandviewresearch.com
Follow Us: